Core Viewpoint - AVITA Medical, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. EST, and management will be available for one-on-one meetings with registered investors [1]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions to optimize wound healing and accelerate patient recovery [3]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [3]. - In the U.S., AVITA Medical holds exclusive rights to manufacture and market PermeaDerm, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3]. International Market Presence - The RECELL System is approved for promoting skin healing in various applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan (excluding RECELL GO) [4].

Core Insights - AVITA Medical's RECELL System is positioned as a standard of care for acute wound treatment, demonstrating significant clinical and economic benefits across various wound types and patient populations [1][3][5] Clinical Evidence - A systematic review of 99 peer-reviewed studies involving over 8,000 patients across 13 countries confirms that the RECELL System consistently delivers strong outcomes, achieving wound closure with less donor skin and faster healing [3][4] - The RECELL System reduces donor site burden by up to 97.55% and meets or exceeds outcomes observed with traditional split-thickness skin grafts (STSG) [7] Economic Impact - Real-world data from the American Burn Association's registry shows that RECELL treatment results in a 36% average reduction in hospital stays, equating to a 5.6-day decrease [4][8] - The estimated cost savings per patient treated with RECELL is over $42,000, allowing hospitals to treat an additional 13 patients per bed annually [8] Patient Outcomes - RECELL treatment leads to improved patient recovery, with 83% of patients discharged home compared to 70% for STSG [8] - The findings highlight the ability of RECELL to accelerate recovery and enhance resource utilization in healthcare settings [5][8]

Core Insights - AVITA Medical, Inc. will report its third quarter 2025 financial results on November 6, 2025, after U.S. market close [1] - A conference call and webcast will be held on the same day to discuss financial results and business highlights [1] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions [3] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [3] - In the U.S., AVITA Medical also has rights to manufacture and exclusively market PermeaDerm, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3] International Market Presence - The RECELL System is approved for various applications in international markets, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan (excluding RECELL GO) [4]

Core Insights - Australia's Medical Services Advisory Committee (MSAC) has recommended amendments to the Medicare Benefits Schedule to include the use of autologous skin cell suspension (ASCS) prepared with RECELL for treating severe acute burn wounds in both adults and children [1][2] Company Overview - AVITA Medical, Inc. is a leading therapeutic acute wound care company focused on delivering transformative solutions that optimize wound healing and accelerate patient recovery [4] - The RECELL System is at the forefront of AVITA Medical's platform, approved by the U.S. Food and Drug Administration for treating thermal burn and trauma wounds [4] Clinical Impact - MSAC's endorsement highlights RECELL's clinical effectiveness, demonstrating that it is as safe and effective as traditional autologous skin grafting while offering superior outcomes in donor site sparing and reducing the need for additional grafting procedures [2][3] - RECELL can shorten hospital stays, alleviate patient pain, and minimize scarring, thus improving overall patient outcomes [2][3] Treatment Applications - The MSAC recommendation supports the use of RECELL for adult patients with burns covering 20% or more of total body surface area (TBSA) and pediatric patients with burns covering 10% or more TBSA, including whole-of-face burn wound closure [7]

Core Points - AVITA Medical has appointed Cary Vance as Interim CEO following the departure of Jim Corbett from the CEO position and the Board [1][4] - The Board plans to engage an executive search firm to find a permanent CEO, considering both internal and external candidates [2] - Cary Vance has over 30 years of experience in the healthcare industry and has held leadership roles in several innovative companies [3] Company Overview - AVITA Medical specializes in therapeutic acute wound care, focusing on innovative solutions to optimize wound healing and accelerate patient recovery [7] - The company's flagship product is the RECELL System, which is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [7][8] - AVITA Medical also holds exclusive rights to market and distribute PermeaDerm and Cohealyx™, enhancing its product portfolio in wound care [7] Financial Performance - Preliminary revenue for the third quarter of 2025 is expected to be approximately $17 million [5][9] - The company has secured a waiver for the third quarter 2025 trailing 12-month net revenue covenant with OrbiMed and is in discussions to redefine future covenants [5] Leadership Transition - Jan Stern Reed has been appointed as Lead Independent Director, supporting the transition in leadership [1][4] - Cary Vance expressed commitment to advancing the company's innovative solutions and focusing on unlocking the full potential of its product portfolio [4]

Core Insights - AVITA Medical, Inc. has received New Technology Add-on Payment (NTAP) reimbursement approval from CMS for its RECELL system, effective October 1, 2025, for treating acute, non-burn trauma and surgical full-thickness wounds [1][2][8] - The NTAP will provide hospitals with supplemental reimbursement of up to $4,875 per case, in addition to standard CMS payments, and will remain in effect until September 30, 2026 [2][8] - The NTAP designation highlights the clinical value and innovation of RECELL, which reduces the need for donor skin and associated complications compared to traditional skin grafting methods [3][4] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on optimizing wound healing and accelerating patient recovery through innovative solutions [5] - The RECELL System, approved by the FDA, utilizes a patient's own skin to create Spray-On Skin Cells, offering a transformative approach to wound treatment [5] - In addition to RECELL, AVITA Medical holds rights to manufacture and distribute PermeaDerm and Cohealyx™, enhancing its product portfolio in the wound care market [5] Clinical Evidence - A multicenter, randomized-controlled trial published in the Journal of Trauma and Acute Care Surgery (2024) demonstrated that RECELL, when used with a widely meshed autograft, achieved comparable wound closure to standard skin grafting while requiring 27% less donor skin [4] - The study indicated that healing and safety outcomes were similar between RECELL and traditional methods, suggesting that RECELL can mitigate donor site complications without compromising results [4]

Core Insights - AVITA Medical, Inc. reaffirms that the RECELL® System significantly reduces hospital length of stay (LOS) by an average of 36% compared to traditional split thickness skin grafts (STSG) for adult patients with deep partial thickness burns [1][2][8] - The RECELL System is clinically validated as a cost-effective option in modern burn management, improving patient outcomes and hospital efficiency [2][5] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions, with the RECELL System at the forefront [6] - The RECELL System utilizes a patient's own skin to create an autologous skin cell suspension autograft, enhancing recovery at the point of care [2][6] Economic Impact - The use of RECELL is associated with potential per patient cost savings exceeding $42,000, based on an average daily inpatient bed cost of $7,554 [3] - The reduction in LOS allows hospitals to treat 13 more patients per bed annually compared to STSG treatment [3] Clinical Findings - A matched analysis of 741 adults showed that RECELL-treated patients had an average 5.6-day reduction in hospital LOS, representing a 36% decrease compared to STSG [2][8] - In 2023, U.S. burn cases consumed over 110,000 ICU days, costing more than $676 million, highlighting the need for efficient burn care solutions [4] Regulatory Approvals - The RECELL System is approved for various applications in international markets, including thermal burn and trauma wounds, with approvals in Australia, Europe, and Japan [7]

Core Viewpoint - AVITA Medical, Inc. is actively engaging with investors through participation in three upcoming investor conferences in September 2025, highlighting its commitment to investor relations and market presence [1][2]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions aimed at optimizing wound healing and accelerating patient recovery [4]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [4]. - In addition to RECELL, AVITA holds exclusive rights in the U.S. for manufacturing and distributing PermeaDerm and Cohealyx™, both of which are innovative wound care products [4]. International Market Presence - The RECELL System is approved for a variety of applications in international markets, including Australia, Europe, and Japan, demonstrating its global reach and regulatory compliance [5]. Upcoming Events - AVITA Medical will host investor meetings at the Cantor Global Healthcare Conference on September 4, 2025, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, 2025 [8]. - A live audio webcast of the Morgan Stanley fireside chat featuring CEO Jim Corbett will be available for replay for 90 days on the company's Investor Relations website [3].

Core Points - AVITA Medical, Inc. has successfully completed a private placement to raise approximately US$15 million (around A$23 million) through the issuance of about 17.2 million New CDIs at an offer price of A$1.32 per New CDI, which represents an 11% discount to the last closing price of A$1.48 on August 12, 2025 [1][4][8] - The proceeds from the placement will be utilized for working capital and to support the growth of the Company's therapeutic acute wound portfolio, expected to sustain operations until free cash flow begins in 2026 [2] - The New CDIs are set to be settled on August 19, 2025, and will commence trading on the ASX on August 20, 2025, ranking equally with existing CDIs [5][6] Company Overview - AVITA Medical is a leading company in therapeutic acute wound care, focusing on innovative solutions that enhance wound healing and accelerate patient recovery [7] - The company's flagship product, the RECELL® System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells [7][9] - AVITA Medical also holds exclusive rights to manufacture and distribute PermeaDerm® and Cohealyx™, further expanding its product offerings in the wound care market [9]

Financial Results - Commercial revenue for Q2 2025 was $18.4 million, representing a 21% increase compared to $15.2 million in Q2 2024 [8][12] - Net loss for Q2 2025 improved to $9.9 million, or a loss of $0.38 per share, compared to a net loss of $15.4 million, or a loss of $0.60 per share in Q2 2024 [8][16] - Total operating expenses decreased to $26.1 million in Q2 2025 from $28.7 million in Q2 2024, primarily due to reductions in sales and marketing expenses [8][14] Business Update - Demand for RECELL was dampened in the first half of 2025 due to delays in provider payments, leading to a backlog of unpaid claims [6][9] - The Centers for Medicare and Medicaid Services (CMS) approved New Technology Add-on Payment (NTAP) for the RECELL System for inpatient trauma wounds [8][10] - AVITA anticipates recovery in RECELL demand in the second half of 2025 as claims backlog is resolved [10] Clinical Highlights - RECELL reduces hospital stays by 36% based on real-world analysis from the national burn registry over five years [5][8] - Cohealyx achieves autograft readiness in as little as five days, with first clinical results published [8] Strategic Developments - The company amended credit terms with OrbiMed, lowering revenue covenants and issuing common stock in lieu of cash payment [8][11] - Michael Tarnoff, MD, FACS, was appointed to the Board of Directors, bringing extensive healthcare leadership experience [8] Guidance Adjustments - Full-year 2025 revenue guidance was revised to a range of $76 million to $81 million, down from previous guidance of $100 million to $106 million [11][15] - The company expects to reach cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026, later than previously anticipated [11][15]